Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vivoryon Therapeutics AG ( (GB:0R3M) ) has shared an announcement.
Vivoryon Therapeutics announced significant progress in its R&D efforts for varoglutamstat, a compound showing promising results in improving kidney function in diabetic kidney disease (DKD). The company’s virtual update highlighted the potential market positioning of varoglutamstat, alongside the introduction of a new development compound, VY2149, and plans for a Phase 2b study. By leveraging a novel mechanism of action targeting inflammation and fibrosis, Vivoryon is positioning itself as a leader in kidney disease treatment, although it has decided to discontinue varoglutamstat’s use in Alzheimer’s disease.
More about Vivoryon Therapeutics AG
Vivoryon Therapeutics AG is a clinical stage company engaged in the discovery and development of small molecule medicines. The company is focused on modulating the activity and stability of pathologically altered proteins, with a market focus on kidney disease treatments.
YTD Price Performance: 4.27%
Average Trading Volume: 3,502
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €54.22M
See more data about 0R3M stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue